Our findings position the GLUT5/fructose metabolic axis as a novel strategy to overcome competition for glucose in appropriate tumour environments, and support optimal mitochondrial function for long-lasting immunosurveillance. This evidence concerns the gene SLC2A5 and neoplasm.